$0.3814
-0.0186-4.65%
Last update: Nov 12, 7:54 AM
Lucid Diagnostics Inc (LUCD) Stock Price, Quote, News & History
LUCDNASDAQ
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
You can purchase shares of Lucid Diagnostics (NASDAQ:LUCD) through any online brokerage.
Other companies in Lucid Diagnostics’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
Lucid Diagnostics has a consensus price target of $3.67.
The stock price for Lucid Diagnostics (NASDAQ: LUCD) is $0.4212 last updated November 12, 2026 at 7:54 AM EST.
There are no upcoming dividends for Lucid Diagnostics.
Lucid Diagnostics does not have any upcoming earnings scheduled.
There is no upcoming split for Lucid Diagnostics.
Lucid Diagnostics is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of...
